POSTER 65

Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor

Melinda J Gooderham, Edward Lain, Robert Bissonnette, Yu-Huei Huang, Charles Lynde, Matthias Hoffmann, Eingun James Song, Jessica H Rubens, Amy M DeLozier, Ming-Chun Hsu, Richard B Warren

< Previous Poster | Next Poster >

Poster 65